Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

Investors

View Stock Information
corporate presentation cover
Corporate Presentation (PDF)

Corporate Profile

Sernova is a regenerative medicine company developing therapeutic technologies with multibillion-dollar market potential for each of its clinical indications.

Press Releases

September 25, 2026
Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
September 10, 2026
Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference
September 8, 2026
Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics
View All Press Releases

Events

September 16, 2026 ET
H.C. Wainwright 28th Annual Global Investment Conference Presentation
September 11, 2026 ET
Sernova Biotherapeutics, Inc. Shareholder Webinar
April 8, 2026 ET
Annual General and Special Meeting of Shareholders
View All Events

IR Contact


David Burke
Vice President, Investor Relations
917.751.5713
david.burke@sernova.com

Email Alerts Sign-Up

Scroll to Top